Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Ultrason Sonochem. 2018 Nov 20;52:184–192. doi: 10.1016/j.ultsonch.2018.11.016

Table 3.

APTT, TT, anti-Xa and anti-IIa activities of unfractionated heparin (UFH), commercial LMWHs and LMWHs produced by US-Fenton system

Sample APTT* IU/mg TT* IU/mg Anti-FXa, IU/mg Anti-FIIa, IU/mg Anti-FXa/Anti-FIIa
UFP 135 135 135 135 1
LMWH-1 64.81±1.31 54.14±2.97 124.11 ± 3.21 81.42 ± 4.22 1.52
LMWH-2 29.87±2.06 <46.42 117.83 ± 4.17 44.76 ± 2.75 2.63
LMWH-3 16.69±0.14 <46.42 81.85 ± 2.84 41.73 ± 1.59 1.96
LMWH-4 <7.58 <46.42 48.98 ± 2.17 37.33 ± 3.52 1.31
Parnaparin 27.64±5.35 <46.42 106.64 ± 5.23 46.71 ± 2.94 2.28
Enoxaparin 29.21±3.00 <46.42 138.03 ± 8.16 39.31 ± 2.33 3.51
Nadroparin 30.58±4.51 <46.42 130.66 ± 1.39 50.33 ± 1.48 2.59

n = 3

*

The activities of agents to prolong APTT, PT, and TT are expressed by the concentration of each agent (IU/mg) that is required to double the APTT, PT, or TT.